Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$17.93 USD
-0.34 (-1.86%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $17.94 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
SNDX 17.93 -0.34(-1.86%)
Will SNDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNDX
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
Other News for SNDX
Syndax Pharmaceuticals: One Down And One To Go
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Syndax and Incyte announce publication of positive Niktimvo results in GVHD
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)